These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 31288345)
1. [Scoping review of active surveillance systems for vaccine safety world-wide]. Cai T; Liu LL; Yao XY; Liu ZK; Yang Y; Meng RR; Zhan SY Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Jul; 53(7):724-730. PubMed ID: 31288345 [No Abstract] [Full Text] [Related]
2. [Develop the active surveillance system for vaccine safety in China]. Cai T; Zhan SY Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Jul; 53(7):664-667. PubMed ID: 31288335 [TBL] [Abstract][Full Text] [Related]
3. Maternal and neonatal data collection systems in low- and middle-income countries for maternal vaccines active safety surveillance systems: A scoping review. Berrueta M; Ciapponi A; Bardach A; Cairoli FR; Castellano FJ; Xiong X; Stergachis A; Zaraa S; Meulen AS; Buekens P; BMC Pregnancy Childbirth; 2021 Mar; 21(1):217. PubMed ID: 33731029 [TBL] [Abstract][Full Text] [Related]
5. Post-licensure rapid immunization safety monitoring program (PRISM) data characterization. Baker MA; Nguyen M; Cole DV; Lee GM; Lieu TA Vaccine; 2013 Dec; 31 Suppl 10():K98-112. PubMed ID: 24331080 [TBL] [Abstract][Full Text] [Related]
6. [Review of near real-time vaccine safety surveillance]. Sun YX; Liu ZK; Nie XL; Zhan SY Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Feb; 42(2):351-356. PubMed ID: 33626627 [TBL] [Abstract][Full Text] [Related]
7. Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system. Alguacil-Ramos AM; Muelas-Tirado J; Garrigues-Pelufo TM; Portero-Alonso A; Diez-Domingo J; Pastor-Villalba E; Lluch-Rodrigo JA Public Health; 2016 Jun; 135():66-74. PubMed ID: 26976484 [TBL] [Abstract][Full Text] [Related]
8. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. Nguyen M; Ball R; Midthun K; Lieu TA Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():291-7. PubMed ID: 22262619 [TBL] [Abstract][Full Text] [Related]
9. Participant-centred active surveillance of adverse events following immunisation: a narrative review. Cashman P; Macartney K; Khandaker G; King C; Gold M; Durrheim DN Int Health; 2017 May; 9(3):164-176. PubMed ID: 28582563 [TBL] [Abstract][Full Text] [Related]
10. Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China. Guo B; Page A; Wang H; Taylor R; McIntyre P Vaccine; 2013 Jan; 31(4):603-17. PubMed ID: 23200940 [TBL] [Abstract][Full Text] [Related]
12. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221 [TBL] [Abstract][Full Text] [Related]
13. Data collection systems for active safety surveillance of vaccines during pregnancy in low- and middle-income countries: developing and piloting an assessment tool (VPASS). Belizán M; Rodriguez Cairoli F; Mazzoni A; Goucher E; Zaraa S; Matthews S; Pingray V; Stergachis A; Xiong X; Berrueta M; Buekens P BMC Pregnancy Childbirth; 2023 Mar; 23(1):172. PubMed ID: 36915061 [TBL] [Abstract][Full Text] [Related]
14. A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program. Baker MA; Lieu TA; Li L; Hua W; Qiang Y; Kawai AT; Fireman BH; Martin DB; Nguyen MD Am J Epidemiol; 2015 Apr; 181(8):608-18. PubMed ID: 25769306 [TBL] [Abstract][Full Text] [Related]
15. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety. Alicino C; Merlano C; Zappettini S; Schiaffino S; Della Luna G; Accardo C; Gasparini R; Durando P; Icardi G Hum Vaccin Immunother; 2015; 11(1):91-4. PubMed ID: 25483520 [TBL] [Abstract][Full Text] [Related]
16. Adverse events following immunization: is this time for the use of WHO causality assessment? Tafuri S; Gallone MS; Calabrese G; Germinario C Expert Rev Vaccines; 2015 May; 14(5):625-7. PubMed ID: 25805053 [TBL] [Abstract][Full Text] [Related]
17. Surveillance of adverse effects following vaccination and safety of immunization programs. Waldman EA; Luhm KR; Monteiro SA; Freitas FR Rev Saude Publica; 2011 Feb; 45(1):173-84. PubMed ID: 21181055 [TBL] [Abstract][Full Text] [Related]
18. Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe. Bonhoeffer J; Black S; Izurieta H; Zuber P; Sturkenboom M Biologicals; 2012 Sep; 40(5):393-7. PubMed ID: 22902972 [TBL] [Abstract][Full Text] [Related]
19. Vaccinovigilance in Europe--need for timeliness, standardization and resources. Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918 [TBL] [Abstract][Full Text] [Related]
20. Vaxtracker: Active on-line surveillance for adverse events following inactivated influenza vaccine in children. Cashman P; Moberley S; Dalton C; Stephenson J; Elvidge E; Butler M; Durrheim DN Vaccine; 2014 Sep; 32(42):5503-8. PubMed ID: 25077424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]